Abstract | PURPOSE: MATERIALS AND METHODS: A prospective, single-arm, multi-center study was performed for 24 weeks. Cinacalcet was administered to patients with intact parathyroid hormone (iPTH) level greater than 300 pg/mL. Cinacalcet was started at a dose of 25 mg daily and titrated until 100 mg to achieve a serum iPTH level<300 pg/mL (primary end point). Early response to cinacalcet was defined as a decrease of iPTH more than 50% within one month. RESULTS: Fifty-seven patients were examined. Based on the magnitude of iPTH decrease, patients were divided into responder (n=47, 82.5%) and non-responder (n=10, 17.5%) groups. Among the responders, 38 achieved the primary end point, whereas 9 patients showed a reduction in serum iPTH of 30% or more, but did not reach the primary end point. Compared to non-responders, responders were significantly older (p=0.026), female (p=0.041), and diabetics (p<0.001). Additionally, early response was observed more frequently in the responders (30/47, 63.8%), of whom the majority (27/30, 90.0%) achieved the primary end point. Multivariate analysis showed that lower baseline iPTH levels [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.93-0.99], the presence of diabetes (OR 46.45, CI 1.92-1125.6) and early response (OR 21.54, CI 2.94-157.7) were significant clinical factors affecting achievement of iPTH target. CONCLUSION:
Cinacalcet was effective in most hemodialysis patients with refractory SHPT. The presence of an early response was closely associated with the achievement of target levels of iPTH.
|
Authors | Jwa-Kyung Kim, Young Joo Kwon, Soo Wan Kim, Yeong-Hoon Kim, Cheol Whee Park, Kyu Bok Choi, Seung Duk Hwang, Kyu Hun Choi |
Journal | Yonsei medical journal
(Yonsei Med J)
Vol. 54
Issue 2
Pg. 453-63
(Mar 01 2013)
ISSN: 1976-2437 [Electronic] Korea (South) |
PMID | 23364981
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Biomarkers, Pharmacological
- Naphthalenes
- Parathyroid Hormone
- Calcium
- Cinacalcet
|
Topics |
- Adult
- Aged
- Biomarkers, Pharmacological
(blood)
- Calcium
(blood)
- Cinacalcet
- Female
- Humans
- Hyperparathyroidism, Secondary
(drug therapy)
- Male
- Middle Aged
- Naphthalenes
(adverse effects, therapeutic use)
- Parathyroid Hormone
(blood)
- Renal Dialysis
- Treatment Outcome
|